Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (October 2012)
20 slides from Anteotech's shareholder meeting presentation, Oct 25, 2012
Slide 1: Anteo Diagnostics Annual General Meeting
For personal use only Anteo Diagnostics (ASX:ADO) Annual General Meeting 25th October 2012 Welcome
Slide 2: Meeting Format
MEETING FORMAT For personal use only • Introductions • Formal Resolutions • Other Business • Meeting Close • CEO Report
Slide 3: Introductions
For personal use only INTRODUCTIONS
Slide 4: Introductions
Introductions For personal use only Anteo Diagnostics Limited Dr Mark Bouris– Non Executive Chairman Richard Martin – Executive Director Sandra Andersen – Non Executive Director Dr Geoff Cumming – CEO Dr Joe Maeji – Chief Scientific Officer Dr Tina Baumgartner – Vice Business President B
Slide 5: Formal Resolutions
For personal use only FORMAL RESOLUTIONS
Slide 6: Resolutions
RESOLUTIONS For personal use only Resolution 1 Adoption of Remuneration Report Resolution 2 Re - Election of Director (Ms Sandra Andersen)
Slide 7: Resolutions – Proxy Count
RESOLUTIONS – PROXY COUNT For personal use only For Against Open Abstain Totals Resolution 1 Adoption of Remuneration Report 52,002,778 2,359,999 Nil 964,000 55,326,777 Re -Election of Director (Ms Sandra Resolution 2 Andersen) 33,494,994 1,419,774 20,323,534 88,475 55,326,777
Slide 8: Other Business and Question Time
For personal use only OTHER BUSINESS AND QUESTION TIME
Slide 9: The Convoluted Path of Progress in Technology Transfer
For personal use only The Convoluted Path of Progress in Technology Transfer Geoff Cumming CEO October 2012
Slide 10: Anteo's Business Development Approach
Anteo’s Business Development Approach For personal use only Identify unmet commercial needs that can be addressed through the use of Mix&Go • Identify industry participants that are likely to benefit from use of Mix&Go • Engage with those companies to explore potential benefits in more detail • Ente
Slide 11: CDA/MTA
CDA/MTA For personal use only Companies enter into Confidential Disclosure Agreements (CDA’s) when they: • Consider doing business together and • Need to know more about one another to assess the benefits • Want to ensure that information disclosed in the process cannot be disclosed to a third party
Slide 12: Current Prospects
Current Prospects For personal use only Anteo now has a total of: • 69 CDA’s • 60 MTA’s in place Usually a CDA precedes an MTA • Recently, given the routine requirement for materials to be exchanged, we have combined the two documents to save time and effort • Many global leading companies are inclu
Slide 13: Service Delivery With Limited Resources
Service Delivery With Limited Resources For personal use only Providing individual support to each recipient of Mix&Go requires a larger service organization than Anteo has. Standardized procedures are being developed: • General Guidelines • Standard Operating Procedures • FAQs and troubleshooting d
Slide 14: Platform Technology
Platform Technology For personal use only Mix&Go is a platform technology - defined as a “technology that has a common starting point but diverges once it is put into actual practice.” Opportunities Challenges • Broadly applicable - many • Broadly applicable – where to markets focus? • Value can be
Slide 15: Case Study
Case Study 1 For personal use only Partner: well-known and reputable manufacturer of products for the R&D market Process: • Convince party of the merits of Mix&Go by generating ten-fold performance improvement compared to commercial product • Work to integrate Mix&Go into product range begins • Comp
Slide 16: Case Study
Case Study 2 For personal use only Partner: start-up company with award winning innovative product Process: • Introduce Mix&Go to company, immediate interest as it addresses an unsolved technical issue • Perform very successful feasibility study • Commence amicable licensing discussions, fast agreem
Slide 17: Case Study
Case Study 3 For personal use only Partner: established global IVD company Process: • Introduce Mix&Go as replacement for current product • Perform very successful small scale feasibility study • Move on very quickly to large scale feasibility study • Encounter problems as they are trying to fit Mix
Slide 18: Case Study
Case Study 4 For personal use only Partner: World-leading supplier of products for the R&D market Process: • Introduce Mix&Go as superior alternative to existing method • Optimize product under conditions specified by partner • Expect licensing discussion Feb 2012 • Partner requires more stringent p
Slide 19: Case Study
Case Study 5 For personal use only Partner: Top 5 worldwide provider of R&D products Process: • Introduce Mix&Go as broadly applicable technology platform useful to improve upon a variety of products • Partner recognizes opportunity, fast MTA turn around and pilot testing • Initial experiments succe
Slide 20: The Best Laid Plans …
The Best Laid Plans … For personal use only • Technology transfer can be a lengthy and tricky process, esp. for platform technologies such as Mix&Go • Delays can occur that are unrelated to Mix&Go performance • Company needs to find balance between pursuing too few and too many opportunities • Too f
Anteo Diagnostics — Shareholder Meeting (October 2012) on 6ix